Scholarlink

Purpose <p>This study aims to evaluate the clinical safety and efficacy of combining microwave ablation (MWA) and percutaneous vertebral augmentation (PVA) for spinal metastases, as this therapeutic approach remains underexplored.</p> Methods <p>Comprehensive searches were conducted in PubMed, Europe PMC, ScienceDirect, and Google Scholar using keywords related to “microwave ablation,” “percutaneous vertebral augmentation,” and “spinal metastasis.” Eligible studies included those reporting pain scores (VAS), opioid consumption, Oswestry Disability Index (ODI), and complications. Meta-analyses performed using RevMan 5.4 and R-Studio 4.5.2.</p> Results <p>Thirteen studies involving 670 patients were included in this analysis. Our meta-analysis revealed improvements in postoperative scores on Day 1 (SMD − 2.46 [95% CI -3.11, -1.81], <i>p</i> &lt; 0.00001), at 1 week (SMD − 3.94 [95% CI; -4.69, -3.20], <i>p</i> &lt; 0.00001), at 1 month (SMD − 4.23 [95% CI; -4.95, -3.51], <i>p</i> &lt; 0.00001), and at 6 months (SMD − 4.01 [95% CI; -4.73, -3.29], <i>p</i> &lt; 0.00001). The Oswestry Disability Index (ODI) showed similar improvements at 1 week (SMD − 2.77 [95% CI; -3.56, -1.98], <i>p</i> &lt; 0.00001), 3 months (SMD − 2.81 [95% CI; -3.51, -2.10], <i>p</i> &lt; 0.00001), and 6 months (SMD − 3.50 [95% CI; -4.55, -2.45], <i>p</i> &lt; 0.00001). Additionally, there was a decrease in opioid consumption at 1 week (MD -60.22 [95% CI; -77.77, -42.66], <i>p</i> &lt; 0.00001), 1 month (MD -91.67 [95% CI; -114.82, -68.52], <i>p</i> &lt; 0.00001), and at 6 months (MD -91.41 [95% CI; -110.47, -72.34], <i>p</i> &lt; 0.00001). Most complications reported are minor complications.</p> Conclusion <p>Microwave ablation combined with PVA effectively treats spinal metastasis, offering pain relief, improved function, and reduced opioid use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The safety and efficacy of combined microwave ablation and percutaneous vertebral augmentation for spinal metastasis: a systematic review and meta-analysis of evidence in the last 6 years

  • 期刊论文

  • 发表日期：

    2026年2月24日

查看全文
  • Alexander Erick Purnomo,
  • Regan Elbert,
  • Yang Yang Endro Arjuna,
  • Jephtah Furano Lumban Tobing

摘要

Purpose

This study aims to evaluate the clinical safety and efficacy of combining microwave ablation (MWA) and percutaneous vertebral augmentation (PVA) for spinal metastases, as this therapeutic approach remains underexplored.

Methods

Comprehensive searches were conducted in PubMed, Europe PMC, ScienceDirect, and Google Scholar using keywords related to “microwave ablation,” “percutaneous vertebral augmentation,” and “spinal metastasis.” Eligible studies included those reporting pain scores (VAS), opioid consumption, Oswestry Disability Index (ODI), and complications. Meta-analyses performed using RevMan 5.4 and R-Studio 4.5.2.

Results

Thirteen studies involving 670 patients were included in this analysis. Our meta-analysis revealed improvements in postoperative scores on Day 1 (SMD − 2.46 [95% CI -3.11, -1.81], p < 0.00001), at 1 week (SMD − 3.94 [95% CI; -4.69, -3.20], p < 0.00001), at 1 month (SMD − 4.23 [95% CI; -4.95, -3.51], p < 0.00001), and at 6 months (SMD − 4.01 [95% CI; -4.73, -3.29], p < 0.00001). The Oswestry Disability Index (ODI) showed similar improvements at 1 week (SMD − 2.77 [95% CI; -3.56, -1.98], p < 0.00001), 3 months (SMD − 2.81 [95% CI; -3.51, -2.10], p < 0.00001), and 6 months (SMD − 3.50 [95% CI; -4.55, -2.45], p < 0.00001). Additionally, there was a decrease in opioid consumption at 1 week (MD -60.22 [95% CI; -77.77, -42.66], p < 0.00001), 1 month (MD -91.67 [95% CI; -114.82, -68.52], p < 0.00001), and at 6 months (MD -91.41 [95% CI; -110.47, -72.34], p < 0.00001). Most complications reported are minor complications.

Conclusion

Microwave ablation combined with PVA effectively treats spinal metastasis, offering pain relief, improved function, and reduced opioid use.